Announced
Completed
Oxford Biomedica completed the acquisition of ABL Europe from Institut Mérieux for €15m.
Financials
Transaction Value£12m
Consideration TypeCash, Ordinary Shares
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-
Tags
biotechs
biopharma
gene therapy
France
Biotechnology
Acquisition
Cross Border
Majority
Private
Friendly
Single Bidder
Completed
Synopsis
Oxford Biomedica, a quality and innovation-led cell and gene therapy CDMO, completed the acquisition of ABL Europe, a cell and gene therapy company, from Institut Mérieux, a microbiology company, for €15m.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.